Dr. Pei has a long track record of significant contributions to the understanding of molecular mechanisms underlying tumor biology. His work has been funded by the National Natural Science Foundation of China. Dr. Pei is a Professor of the Department of Pathology at Xuzhou Medical University. Dr. Pei has published more than 150 scientific publications, with 20 corresponding authorship papers in top academic journals such as Cell Death and Differentiation, Signal Transduction and Targeted Therapy, Oncogene, Molecular Cancer, Clinical and Translational Medicine，Brain，Journal of Experimental & Clinical Cancer Research and Cell Death & Disease. He has received several awards for his academic achievement. Dr. Pei has extensive experience in Cancer cell biology, particularly in carcinogenesis, cancer therapy and prevention.

Academic Awards

Dr. PEI DongSheng received many prestigious academic awards.

2009 Science and Technology award of Jiangsu Province

2009 Science and Technology award of Education Ministry

2010 Science and Technology award of Jiangsu Province

2011 National Science and Technology award

2015 Science and Technology award of Jiangsu Province

2016 Science and Technology award of Education Ministry

2024 Science and Technology award of Jiangsu Education Department

Publications

Representative publications: 

1.Jiang X, Zhu Z, Ding L, Du W, Pei D*. ALKBH4 impedes 5-FU Sensitivity through suppressing GSDME induced pyroptosis in gastric cancer. Cell Death Dis. 2024 Jun 20;15(6):435.

2.Du W, Quan X, Wang C, Song Q, Mou J, Pei D*^. Regulation of tumor metastasis and CD8+ T cells infiltration by circRNF216/miR-576-5p/ZC3H12C axis in colorectal cancer. Cell Mol Biol Lett. 2024;29(1):19.

3.Liao M, Sun X, Zheng W, Wu M, Wang Y, Yao J, Ma Y, Gao S, Pei D*. LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter. Mol Cancer. 2023;22(1):163.

4.Du WQ, Zhu ZM, Jiang X, Kang MJ, Pei DS*. COPS6 promotes tumor progression and reduces CD8+ T cell infiltration by repressing IL-6 production to facilitate tumor immune evasion in breast cancer. Acta Pharmacol Sin. 2023 Sep;44(9):1890-1905.

5.Huo FC, Zhu ZM, Du WQ, Pan YJ, Jiang X, Kang MJ, Liu BW, Mou J, Pei DS*. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5. Pharmacol Res. 2023 Jul 20;195:106863.

6.Pan YJ, Huo FC, Kang MJ, Liu BW, Wu MD, Pei DS*. Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer. Clin Transl Med. 2022 Nov;12(11):e1113.

7.Du QY, Huo FC, Du WQ, Sun XL, Jiang X, Zhang LS, Pei DS*. METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA. Oncogene. 2022 Sep;41(39):4420-4432.

8.Huo FC, Zhu ZM, Du QY, Pei DS*. PAK5-stabilized Smuc confers renal cell carcinoma metastasis. Clin Transl Med. 2021 Sep;11(9):e559.

9.Zhang DG, Gong CC, Wu XJ, Ren X, Sedaka RS, Chen WC, Huo FC, Chen C, Du WQ, Pei DS*. P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer. Signal Transduct Target Ther. 2021 Feb 5;6(1):47.

10.Huo FC, Pan YJ, Li TT, Mou J, Pei DS*. PAK5 promotes the migration and invasion of cervical cancer cells by phosphorylating SATB1. Cell Death Differ. 2019 Jun;26(6):994-1006.